Molecular and phenotypic profiles of carbapenem- and third-generation cephalosporin-resistant Klebsiella pneumoniae isolates from the fecal microbiota of pediatric patients with COVID-19.

Publication date: Jul 23, 2026

Gut colonization with multidrug-resistant (MDR) Klebsiella pneumoniae is commonly associated with an increased risk of extraintestinal infections among hospitalized patients. Extensive antibiotic exposure during the COVID-19 pandemic, is a critical contributing factor for the emergence of resistant strains. This investigation sought to elucidate the phenotypic and molecular resistance traits of carbapenem-resistant K. pneumoniae (CRKP) and extended-spectrum β-lactamase-producing K. pneumoniae (ESBL-KP) colonizing the gut of pediatric patients with confirmed COVID-19. A cross-sectional study was conducted from October 2020 to March 2022 at a tertiary pediatric hospital in Fayoum, Egypt. Fecal samples were collected from hospitalized pediatric COVID-19 patients. K. pneumoniae isolates were identified using standard microbiological methods. Antimicrobial susceptibility testing was carried out in accordance with the CLSI guidelines. ESBL and carbapenemase production were assessed phenotypically, while resistance genes were detected by multiplex and uniplex PCR. Microtiter plate method was used to assess biofilm formation. K. pneumoniae was detected in 36 of 71 patients (50. 7%) using antibiotic-supplemented selective culture. The isolated strains were exclusively resistant, including 22 CRKP and 14 ESBL-KP. Colistin susceptibility was maintained in all isolates. CRKP strains showed significantly increased rate of resistance to fluoroquinolones and amikacin compared with ESBL-KP. Bla gene (54. 5%) and bla (45. 5%) were detected among CRKP isolates. ESBL-associated genes bla, bla, and bla were prevalent in both groups. Biofilm formation was common and comparable between CRKP and ESBL-KP isolates. A high prevalence of fecal carriage of MDR K. pneumoniae, driven by carbapenemase-producing strains, was observed among hospitalized pediatric COVID-19 patients. These outcomes highlight the necessity for routine colonization surveillance, optimized antimicrobial stewardship, and strengthened infection control strategies in pediatric settings.

Open Access PDF

Concepts Keywords
Klebsiella Carbapenem resistance
October ESBL
Optimized Gut colonization
Pcr Klebsiella pneumoniae
Pneumoniae Pediatric COVID-19

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infections
disease MESH strains
pathway KEGG Biofilm formation
drug DRUGBANK Colistin
drug DRUGBANK Amikacin
disease MESH Long Covid
pathway REACTOME Reproduction
disease MESH included
drug DRUGBANK Coenzyme M
disease MESH pneumonia
disease MESH bloodstream infections
drug DRUGBANK Isoxaflutole
disease MESH ics
drug DRUGBANK L-Isoleucine
disease MESH inflammation
disease MESH CTX
drug DRUGBANK Tretamine
disease MESH car
disease MESH co infection
disease MESH Char
drug DRUGBANK Ademetionine
disease MESH mul
disease MESH hypoxia
drug DRUGBANK Oxygen
drug DRUGBANK Medical air
disease MESH respiratory failure
disease MESH shock
disease MESH syndrome
drug DRUGBANK Cefotaxime
drug DRUGBANK Meropenem
drug DRUGBANK Cefepime
drug DRUGBANK Amoxicillin
drug DRUGBANK Gentamicin
drug DRUGBANK Levofloxacin
disease MESH MHA
drug DRUGBANK Aztreonam
disease MESH septic shock
disease MESH hydrocephalus
drug DRUGBANK Methyl isocyanate
disease MESH Gastroenteritis
disease MESH cardiomyopathy
disease MESH Intussusception
drug DRUGBANK Ceftriaxone

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *